Background And Aims: Transition from intravenous (IV) to subcutaneous (SC) administration is an option in inflammatory bowel disease (IBD) with Infliximab (IFX) or Vedolizumab (VDZ). The aim was to compare the adherence, the persistence in therapy, and quality of life (QoL) at baseline, at 6, at 12 months of SC IFX versus SC VDZ.
Methods: This was a prospective, observational, multicenter study on patients with IBD in treatment with IV IFX or VDZ who switched to SC. All patients investigated the QoL by the short IBD Questionnaire (sIBDQ) and the concerns and expectations by a 6-item survey. Any adverse events, local and systemic, were reported. Safety, concerns, and satisfaction were evaluated.
Results: One hundred and eight out of 93 patients were replaced, 51 to SC IFX and 42 to SC VDZ. The majority accepted the SC route. Persistence in therapy was similar between the two groups. The QoL improved after 6 months (p = 0.004), but at T12 both groups show a significant decline in QoL. SC administration has not caused any concern for patients. As safety, both groups reported a similar number of local reactions (IFX 19.60% vs VDZ 19.04%). In the IFX group were reported more systemic reactions (IFX 11.6% vs VDZ 7.14%) without the need for hospitalization.
Conclusion: The transition from IV to SC administration is an appropriate and safe option for treatment with IFX or VDZ. It is very important to consider the patient's choice and preference. The SC administration led to a significant benefit in QoL, especially in the first 6 months of therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10620-024-08631-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment of immune checkpoint inhibitor-related colitis: a narrative review.
Transl Cancer Res
December 2024
Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background And Objective: Cancer is one of the most difficult diseases facing modern medicine, and increasing amounts of research and clinical treatments are being applied to the treatment of cancer. Immunotherapy, particularly immune checkpoint inhibitor (ICI) therapy, has revolutionized the treatment and overall survival of patients with several different types of cancer. Approximately one-third of patients treated with ICIs may experience immune-related adverse events (irAEs).
View Article and Find Full Text PDFIntroduction: Biologic therapies treat patients with moderate to severe inflammatory bowel disease (IBD). This study aims to investigate the demographics of biologic therapy use and its association with patient characteristics, a topic that has not yet been thoroughly assessed in our region.
Methods: Electronic health record data from June 1, 2021, to May 31, 2023, were collected at a tertiary care IBD center in Kuwait.
Comparison of clinical and endoscopic efficacy between vedolizumab and infliximab in bio-naïve patients with ulcerative colitis: a multicenter, real-world study.
Therap Adv Gastroenterol
October 2024
Department of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, No. 26 Yuancun Road II, Tianhe District, Guangzhou 510000, China.
Article Synopsis
- A study compared the effectiveness of two biologic therapies, vedolizumab (VDZ) and infliximab (IFX), in treating ulcerative colitis (UC) in patients who had never used biologics before.
- Conducted across five centers, it involved 199 patients and measured outcomes such as remission and healing at 14 and 52 weeks after starting treatment.
- Results showed that while both therapies were similar at 14 weeks, VDZ outperformed IFX in remission and healing rates at 52 weeks, with no significant differences in adverse effects between the two treatments.
Transition to Subcutaneous Infliximab vs Vedolizumab in Inflammatory Bowel Disease: A Prospective Multicenter Study.
Dig Dis Sci
December 2024
Gastroenterology Unit, DiMePreJ, "Aldo Moro" University, Bari, Italy.
Background And Aims: Transition from intravenous (IV) to subcutaneous (SC) administration is an option in inflammatory bowel disease (IBD) with Infliximab (IFX) or Vedolizumab (VDZ). The aim was to compare the adherence, the persistence in therapy, and quality of life (QoL) at baseline, at 6, at 12 months of SC IFX versus SC VDZ.
Methods: This was a prospective, observational, multicenter study on patients with IBD in treatment with IV IFX or VDZ who switched to SC.
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study.
Eur J Clin Invest
November 2024
Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy.
Article Synopsis
- Subcutaneous formulations of infliximab (IFX) and vedolizumab (VDZ) are effective treatments for inflammatory bowel diseases (IBDs) and this study evaluated the impact of switching from intravenous to subcutaneous forms.
- The analysis included data from 231 adult patients with Crohn's disease or ulcerative colitis, assessing clinical remission rates at 3, 6, and 12 months post-switch.
- Results showed that most patients remained in remission after switching, and switching early in the treatment process was associated with a lower risk of negative therapeutic outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!